| Autophagy as a new therapeutic target in Duchenne muscular dystrophy C De Palma, F Morisi, S Cheli, S Pambianco, V Cappello, M Vezzoli, ... Cell death & disease 3 (11), e418-e418, 2012 | 271 | 2012 |
| Remodeling of the chromatin structure of the facioscapulohumeral muscular dystrophy (FSHD) locus and upregulation of FSHD-related gene 1 (FRG1) expression … B Bodega, GDC Ramirez, F Grasser, S Cheli, S Brunelli, M Mora, ... BMC biology 7, 1-15, 2009 | 109 | 2009 |
| DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan FS Falvella, S Cheli, A Martinetti, C Mazzali, R Iacovelli, C Maggi, ... British journal of clinical pharmacology 80 (3), 581-588, 2015 | 78 | 2015 |
| Expression profiling of FSHD-1 and FSHD-2 cells during myogenic differentiation evidences common and distinctive gene dysregulation patterns S Cheli, S François, B Bodega, F Ferrari, E Tenedini, E Roncaglia, ... PloS one 6 (6), e20966, 2011 | 61 | 2011 |
| The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions C Rafaniello, M Sessa, FF Bernardi, M Pozzi, S Cheli, D Cattaneo, ... The pharmacogenomics journal 18 (3), 422-430, 2018 | 56 | 2018 |
| Autophagy as a new therapeutic target in Duchenne muscular dystrophy C De Palma, F Morisi, S Cheli, S Pambianco, V Cappello, M Vezzoli, ... Cell Death & Disease 5 (8), e1363, 2014 | 28 | 2014 |
| Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase FS Falvella, M Caporale, S Cheli, A Martinetti, R Berenato, C Maggi, ... International journal of molecular sciences 16 (4), 8884-8895, 2015 | 25 | 2015 |
| Neonatal outcomes in maternal depression in relation to intrauterine drug exposure S Corti, P Pileri, MI Mazzocco, C Mandò, AF Moscatiello, D Cattaneo, ... Frontiers in pediatrics 7, 309, 2019 | 24 | 2019 |
| Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients? F Nichetti, FS Falvella, R Miceli, S Cheli, R Gaetano, G Fucà, G Infante, ... The Pharmacogenomics Journal 19 (5), 465-472, 2019 | 23 | 2019 |
| Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral … A Giacomelli, A Riva, FS Falvella, ML Oreni, D Cattaneo, S Cheli, ... BMC infectious diseases 18, 1-8, 2018 | 22 | 2018 |
| Pharmacokinetics and pharmacogenetics of selective serotonin reuptake inhibitors during pregnancy: an observational study L Pogliani, FS Falvella, D Cattaneo, P Pileri, AF Moscatiello, S Cheli, ... Therapeutic Drug Monitoring 39 (2), 197-201, 2017 | 21 | 2017 |
| The first steps towards the era of personalised vaccinology: predicting adverse reactions P Pellegrino, FS Falvella, V Perrone, C Carnovale, T Brusadelli, M Pozzi, ... The Pharmacogenomics Journal 15 (3), 284-287, 2015 | 20 | 2015 |
| Therapeutic drug monitoring and pharmacogenetics of antipsychotics and antidepressants in real life settings: A 5-year single centre experience S Baldelli, S Cheli, C Montrasio, D Cattaneo, E Clementi The World Journal of Biological Psychiatry 22 (1), 34-45, 2021 | 18 | 2021 |
| Levofloxacin-induced seizures in a patient without predisposing risk factors: the impact of pharmacogenetics C Gervasoni, D Cattaneo, FS Falvella, P Vitiello, S Cheli, L Milazzo, ... European journal of clinical pharmacology 69, 1611-1613, 2013 | 17 | 2013 |
| Clinical and genetic determinants of nevirapine plasma trough concentration A Giacomelli, S Rusconi, FS Falvella, ML Oreni, D Cattaneo, V Cozzi, ... SAGE Open Medicine 6, 2050312118780861, 2018 | 15 | 2018 |
| The role of Toll-like receptor 4 polymorphisms in vaccine immune response P Pellegrino, FS Falvella, S Cheli, C Perrotta, E Clementi, S Radice The Pharmacogenomics Journal 16 (1), 96-101, 2016 | 15 | 2016 |
| SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir L Milazzo, AM Peri, C Mazzali, C Magni, E Calvi, A De Nicolo, E Clementi, ... Journal of Antimicrobial Chemotherapy 70 (4), 1155-1160, 2015 | 15 | 2015 |
| Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer … FS Falvella, C Cremolini, R Miceli, F Nichetti, S Cheli, C Antoniotti, ... The Pharmacogenomics Journal 17 (4), 331-336, 2017 | 14 | 2017 |
| Autophagy as a new therapeutic target in Duchenne muscular dystrophy. Cell Death Dis 3: e418 C De Palma, F Morisi, S Cheli, S Pambianco, V Cappello, M Vezzoli, ... | 13 | 2012 |
| ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment S Cheli, S Baldelli, A De Silvestri, M Fusi, D Minisci, C Gervasoni, ... The Pharmacogenomics Journal 21 (5), 586-593, 2021 | 11 | 2021 |
